OEP Pharma is a full-service, global pharmaceutical company. Leveraging its R&D capabilities and commercial infrastructure in Asia, OEP Pharma develops, manufactures, and commercializes branded and generic medicines. OEP Pharma is the U.S. headquarters of OEP Group, a TWSE-listed pharmaceutical company founded in Taiwan in 1982. With a market cap of $200 million USD and 1000 employees worldwide, OEP has a 40-year track record as a distributor of choice in Taiwan and ASEAN countries. Today, OEP has a growing generics and specialty pharma product portfolio and pipeline, experienced salesforce in 10 countries, and distribution partners in North America. Its FDA-approved oral dosage facility, and injectables facility (FDA approval expected early 2021) specialize in complex formulations, including highly potent compounds, modified release products, and poorly soluble compounds.